Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This project explores the role and mechanism of ulinastatin in preventing cardiac dysfunction
caused by cardiopulmonary bypass by reducing cardiac endothelial permeability through
clinical research. Our previous basic research has found that inhibiting the
TK/B1R/ARNT/MMP3/iNOS signaling axis in the acute phase of cardiac R/I can reduce the
permeability of cardiac endothelial cells, reduce cardiac edema and improve cardiac function
(this part has been completed) . This study intends to investigate the effects of ulinastatin
on 24-hour cardiac function and prognosis in patients undergoing cardiac surgery undergoing
cardiopulmonary bypass (cardiac function, inflammatory indicators, coagulation function,
capillary leakage indicators, 28-day survival time, CCU time). At the same time, we observed
the dynamic changes of TK/B1R/MMP3 during cardiopulmonary bypass in patients undergoing
cardiac surgery and explored its relationship with prognosis, as well as the effect of
ulinastatin intervention on TK/B1R/MMP3 before and after cardiopulmonary bypass.